Payment overview · 2025
General Payments
$1,152.13
17 reported records · 11 companies
Healthcare provider profile · identity verified
Sarah L Brewer, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · KIRKSVILLE, MO · NPI 1902829963
Verified facts
What the public records show
CMS Open Payments records show Sarah L Brewer, D.O. received $1,152.13 in general payments during 2025 across 17 reported records.
PENTAX of America, Inc. accounted for 77.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PENTAX of America, Inc. | Unresolved — no canonical attribution shown | $891.14 | 77.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.50 | 4.1% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $39.85 | 3.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.46 | 3.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.55 | 2.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.04 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.82 | 1.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.69 | 1.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.27 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.94 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.87 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $891.14 | 4 |
| Food and Beverage | $260.99 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PENTAX Medical Normalized: pentax medical |
Device | PENTAX of America, Inc. | $891.14 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.50 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $39.85 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.55 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.55 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 177 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
183 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 367 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 349 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 300 | 54 |
| Omeprazole | Omeprazole | 260 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 214 | 38 |
| Lisinopril | Lisinopril | 196 | 38 |
| Simvastatin | Simvastatin | 192 | 36 |
| Losartan Potassium | Losartan Potassium | 190 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 187 | 31 |
| Eliquis | Apixaban | 183 | 25 |
| Potassium Chloride | Potassium Chloride | 181 | 28 |
| Jardiance | Empagliflozin | 177 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 162 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 26 |
| Furosemide | Furosemide | 148 | 27 |
| Carvedilol | Carvedilol | 144 | 23 |
| Gabapentin | Gabapentin | 117 | 31 |
| Sertraline Hcl | Sertraline Hcl | 111 | 16 |
| Metformin Hcl | Metformin Hcl | 108 | 26 |
| Metformin Hcl Er | Metformin Hcl | 105 | 19 |
| Atenolol | Atenolol | 104 | 16 |
| Ozempic | Semaglutide | 103 | 18 |
| Spironolactone | Spironolactone | 103 | 19 |
| Ezetimibe | Ezetimibe | 99 | 17 |
| Celecoxib | Celecoxib | 92 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 30 |
| Alendronate Sodium | Alendronate Sodium | 91 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 19 |
| Allopurinol | Allopurinol | 86 | 17 |
| Tramadol Hcl | Tramadol Hcl | 85 | 20 |
| Meloxicam | Meloxicam | 83 | 16 |
| Benazepril Hcl | Benazepril Hcl | 78 | 15 |
| Pregabalin | Pregabalin | 78 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 76 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 17 |
| Trulicity | Dulaglutide | 72 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 12 |
| Famotidine | Famotidine | 59 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 12 |
| Trazodone Hcl | Trazodone Hcl | 58 | 12 |
| Topiramate | Topiramate | 56 | 12 |
| Farxiga | Dapagliflozin Propanediol | 53 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 12 |
| Glimepiride | Glimepiride | 49 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 49 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | suppressed |
| Finasteride | Finasteride | 43 | suppressed |
| Bumetanide | Bumetanide | 42 | suppressed |
| Nabumetone | Nabumetone | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Ranolazine Er | Ranolazine | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Gemfibrozil | Gemfibrozil | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Prednisone | Prednisone | 37 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | 12 |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Victoza 2-Pak | Liraglutide | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Sutab | Sod Sulf/Pot Chloride/Mag Sulf | 13 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Alphagan P | Brimonidine Tartrate | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Travoprost | Travoprost | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,152.13 · 17 records | PENTAX of America, Inc. | EVENITY, FREESTYLE LIBRE 3, JARDIANCE, Omnipod, PENTAX Medical, PROLIA, QULIPTA, SHINGRIX, UBRELVY, VYNDAMAX, Veozah, WATCHMAN Access System, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error